Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Revenues Increase 25%

Published: Wednesday, January 29, 2014
Last Updated: Wednesday, January 29, 2014
Bookmark and Share
Company announces financial results for the fourth quarter and fiscal year 2013.

Fourth quarter 2013 results: 

  • Revenue of $387 million, a 25% increase compared to $309 million in the fourth quarter of 2012 
  • GAAP net income for the quarter of $81 million, or $0.56 per diluted share, compared to $72 million, or $0.53 per diluted share, for the fourth quarter of 2012 
  • Non-GAAP net income for the quarter of $65 million, or $0.45 per diluted share, compared to $57 million, or $0.42 per diluted share, for the fourth quarter of 2012 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures) 
  • Cash flow from operations of $127 million and free cash flow of $100 million for the quarter 

Gross margin in the fourth quarter of 2013 was 66.9% compared to 65.8% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangible assets, legal contingencies, and inventory revaluation adjustments, non-GAAP gross margin was 71.4% for the fourth quarter of 2013 compared to 68.5% in the prior year period. 

Research and development (R&D) expenses for the fourth quarter of 2013 were $76.7 million compared to $56.9 million in the fourth quarter of 2012. R&D expenses included $10.9 million and $8.0 million of non-cash stock compensation expense in the fourth quarters of 2013 and 2012, respectively. Excluding these charges and contingent compensation, R&D expenses as a percentage of revenue were 17.0% compared to 15.4% in the prior year period. 

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2013 were $111.6 million compared to $79.7 million for the fourth quarter of 2012. SG&A expenses included $16.8 million and $14.1 million of non-cash stock compensation expense in the fourth quarters of 2013 and 2012, respectively. Excluding these charges, contingent compensation and amortization of acquired intangible assets, SG&A expenses as a percentage of revenue were 22.2% compared to 19.9% in the prior year period. 

Depreciation and amortization expenses were $27.2 million and capital expenditures were $27.3 million during the fourth quarter of 2013. The Company ended the fourth quarter of 2013 with $1.17 billion in cash, cash equivalents and short-term investments, compared to $1.35 billion as of December 30, 2012. 

Fiscal 2013 results: 

  • Revenue of $1.42 billion, a 24% increase over the $1.15 billion reported in fiscal 2012 
  • GAAP net income of $125 million, or $0.90 per diluted share, compared to $151 million, or $1.13 per diluted share in fiscal 2012 
  • Non-GAAP net income of $250 million, or $1.80 per diluted share, compared to $210 million, or $1.59 per diluted share, in fiscal 2012 (see table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures) 

Gross margin for fiscal 2013 was 64.2% compared to 67.4% in fiscal 2012. Cost of product sales during 2013 included impairment charges of $25.2 million related to a decision to discontinue a non-core product line. Excluding the effect of these charges as well as non-cash charges associated with stock compensation, amortization of acquired intangible assets, legal contingencies, and inventory revaluation adjustments, non-GAAP gross margin was 70.1% for fiscal 2013 compared to 69.7% in fiscal 2012. 

R&D expenses for fiscal 2013 were $276.7 million compared to $231.0 million in fiscal 2012. R&D expenses included $37.4 million and $30.9 million of non-cash stock compensation expense in fiscal 2013 and 2012, respectively. R&D expenses for fiscal 2012 included an impairment charge of $21.4 million related to an in-process research and development asset. Excluding these charges and contingent compensation, R&D expenses as a percentage of revenue were 16.8% compared to 15.3% in the prior year. 

SG&A expenses for fiscal 2013 were $381.0 million compared to $286.0 million in fiscal 2012. SG&A expenses included $61.4 million and $55.4 million of non-cash stock compensation expense in fiscal 2013 and 2012, respectively. Excluding these charges, contingent compensation, and amortization of acquired intangible assets, SG&A expenses as a percentage of revenue were 20.8% compared to 19.5% in the prior year. 

"The fourth quarter capped off a spectacular year for Illumina with robust performance across all products and geographies," stated Jay Flatley, CEO. "We made significant progress on key R&D programs which allowed us to introduce new products in early 2014 that will once again redefine the trajectory of sequencing. We plan to leverage this momentum in 2014 to more broadly enable the adoption of genomics." 

Updates since last earnings release: 

Introduced HiSeq XTM Ten Sequencing System, enabling 'factory scale' sequencing and announced sales to Macrogen, the Broad Institute, the Garvan Institute of Medical Research, and the New York Genome Center 

Launched NextSeqTM 500 Sequencing System, a new platform that packs high-throughput performance into an affordable desktop sequencer 

Announced plans to simplify library preparation with NeoPrepTM, a push-button, library-preparation system 

Launched BaseSpace® OnSite, a simple informatics appliance that enables users to securely stream data to a local, private cloud 

Unveiled new enhancements to the HiSeq® family of instruments, which will enable certain HiSeq instruments to produce 1 terabase of sequencing data 

Announced that Illumina received premarket clearance from the U.S. Food and Drug Administration (FDA) for the MiSeqDxTM system, MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit 

Acquired NextBio, a leader in analyzing and aggregating complex genomic data 

Entered into multi-year licensing agreements with Quest Diagnostics and LabCorp to use Illumina's NGS technology for clinical laboratory testing 

Entered into an agreement with Amgen to develop an Oncology Companion Diagnostic Test on the FDA-Cleared MiSeqDx NGS Instrument 

Further strengthened Illumina's management team by appointing Francis deSouza to the role of President 

Additional updates not highlighted above can be found on our investor relations webpage: http://investor.illumina.com 

Financial outlook and guidance 
The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures. 

For fiscal 2014 the Company is projecting approximately 15% to 17% revenue growth and non-GAAP earnings per fully diluted share of $2.00 to $2.06. These projections assume full year non-GAAP gross margin of approximately 70.0%, a pro forma tax rate of approximately 29.5% and stock compensation expense of approximately $128 million. Full-year weighted average diluted shares outstanding, for the measurement of pro forma amounts, is expected to be approximately 148 million shares assuming a stock price of $114.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Illumina, Inc. has announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Thursday, January 28, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Illumina Launches Cancer Screening Company
Formation of GRAIL seen as a significant development in the war on cancer.
Monday, January 11, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™
A revolutionary next-generation sequencing service for epidemiological monitoring of bacterial infections.
Tuesday, December 15, 2015
Illumina Accelerator Announces Third Funding Cycle of Genomics Startups
Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups.
Thursday, December 10, 2015
Desktop Genetics Receives Strategic Investment from Illumina
Illumina invests in Desktop Genetics' technology to support the platform's integration with NGS pipelines and improve CRISPR genome editing workflows.
Thursday, December 10, 2015
Almac Group, Illumina Collaborate
Almac Diagnostics today announced that it had entered into a collaboration with Illumina, Inc. to establish a framework for the development of next-generation sequencing (NGS)-based companion diagnostic assays.
Friday, November 13, 2015
Illumina Announces New $250 Million Share Repurchase Authorization
Company completed repurchase of $96 million under previous share repurchase program.
Tuesday, November 03, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Scientific News
Milestone Resource in Wheat Research Now Available for Download
Leading on from The Genome Analysis Centre’s (TGAC) previous announcement of their new bread wheat genome assembly, the landmark resource is now publically available to download at the European Bioinformatics Institute’s (EMBL-EBI) Ensembl database for full analysis.
Tracing a Cellular Family Tree
New technique allows tracking of gene expression over generations of cells as they specialize.
Minor Flu Strains Pack a Bigger Punch
Minor variants of flu strains, which are not typically targeted in vaccines, carry a bigger viral punch than previously realized, a team of scientists has found.
Euformatics Partners With EMQN, UK NEQAS
Euformatics has announced a strategic partnership with the largest External Quality Assessment (EQA) scheme providers in Europe – EMQN and UK NEQAS for Molecular Genetics.
Precision Medicine for Penile Cancer
Defining the genomic landscape reveals similarities with other squamous cell cancers.
Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
Carsten Flohr and his research group at St Thomas’s hospital, London are currently investigating the interaction between skin and gut microbiota in relation to the associated risk of atopic eczema (AE) and food allergy in infants.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.
Proteins Crucial to Loss of Hearing Identified
Proteins play key role in genes that help auditory hair cells grow.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.
Far-reaching Genetic Study of 1,000 UK People
300,000 gene variants from 1,000 people made publically available via F1000Research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!